- Home
- ANGX vs AQST Comparison
ANGX vs AQST Comparison
Compare ANGX & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGX | AQST |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | 311 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 546.0M | 529.4M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | ANGX | AQST |
|---|---|---|
| Price | $3.54 | $4.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $9.75 | $9.00 |
| AVG Volume (30 Days) | 1.2M | ★ 2.2M |
| Earning Date | 04-30-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | $46.23 | $10.08 |
| Revenue Next Year | $25.81 | $49.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $2.05 | $2.94 |
| 52 Week High | $18.90 | $7.55 |
Technical Indicators
Market Signals| Indicator | ANGX | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 62.13 | 46.13 |
| Support Level | $3.03 | $3.84 |
| Resistance Level | $3.97 | $4.38 |
| Average True Range (ATR) | 0.25 | 0.25 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 79.82 | 7.41 |
Price Performance
Historical ComparisonAbout ANGX Angel Studios Inc.
Angel Studios Inc is an entertainment company known for crowd-funded films and television projects. It enables creators to share projects and engage audiences directly. The platform allows fans to invest in and promote productions, fostering a community-driven approach to content creation.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.